Looking Ahead: What’s on the Horizon in Advanced Melanoma
Panelists discuss how emerging advances in melanoma treatment include next-generation tumor-infiltrating lymphocyte therapy, oncolytic immunotherapy, bispecific antibodies, cancer vaccines, and neoadjuvant approaches that may allow de-escalation of both surgery and systemic therapy while improving treatment-free survival.
EP: 1.The Evolving Treatment Paradigm in Melanoma: Targeted Therapy vs Immunotherapy
EP: 2.Frontline Treatment Options for Melanoma
EP: 3.Clinical Perspectives: Single-Agent Vs Combination Immunotherapy for Melanoma
EP: 4.Combination Immunotherapy Strategies in Melanoma: Insights From Key Trials
EP: 5.Managing Expectations: Adverse Events With Melanoma Immunotherapy
EP: 6.Immunotherapy Dosing Strategies: Optimizing Efficacy and Managing Toxicity in Melanoma
EP: 7.Balancing Efficacy and Safety: Toxicity Considerations With Melanoma Immunotherapy
EP: 8.Navigating Newer Treatment Regimens in Melanoma: Practical Approaches to Dosing and Adverse Event Management
EP: 9.Sequencing Melanoma Treatments: Strategies for Optimizing Patient Outcomes
EP: 10.Looking Ahead: What’s on the Horizon in Advanced Melanoma
Future Directions in Melanoma Treatment
Key Discussion Points:
- Emerging therapies and treatment approaches in melanoma
- Role of biomarkers in treatment selection
- Neoadjuvant and de-escalation strategies
Key Points for Physicians:
- Promising emerging therapies include next-generation tumor-infiltrating lymphocytes (TIL) therapy, oncolytic immunotherapy (RP-1 with PDUFA date of July 22), bispecific antibodies, and cancer vaccines (Moderna melanoma vaccine)
- Practice-changing neoadjuvant data includes S1801 with pembrolizumab, NADINA with ipilimumab/nivolumab, showing potential for de-escalation of both systemic therapy and surgery
- Critical need for predictive biomarkers for both efficacy and toxicity, particularly for adjuvant therapy where many patients may be overtreated
Notable Insights:
Neoadjuvant immunotherapy approaches have demonstrated significant promise, with potential for de-escalation of both surgical extent and total systemic therapy duration—patients achieving pathological complete response after neoadjuvant therapy may require only 6 weeks of treatment.
Clinical Significance:
The melanoma treatment landscape continues to evolve rapidly with multiple promising therapeutic approaches in development, though predictive biomarkers remain a critical unmet need to optimize patient selection and treatment sequencing.
